Replimune Group, Inc.

REPL

Healthcare Biotechnology

EPS
+39.7%
Free cash flow
+42.2%
Total debt
+74.3%

Quarter to September 2026, against a year earlier

21.88 1.40 −6.01%
Market cap
$2.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−928.3%
Net debt / EBITDA
0.5×
Dividend safety
n/a

Replimune Group, Inc. (REPL) Operating margin

Alert me on Operating margin

Replimune Group, Inc.'s operating margin over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2026 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2026) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2026 0.00% 0.00
FY2025 0.00% 0.00
FY2024 0.00% 0.00
FY2023 0.00% 0.00
FY2022 0.00% 0.00
FY2021 0.00% 0.00
FY2020 0.00% 0.00
FY2019 0.00% 0.00
FY2018 0.00% 0.00
FY2017 0.00% —

Quarterly newest first

Period Operating margin Change (points)
Sep 2026 0.00% 0.00
Jun 2026 0.00% 0.00
Mar 2026 0.00% 0.00
Dec 2025 0.00% 0.00
34 more quarters

Against its own ten years

Low 0.00% High 0.00%
Ten-year median 0.00%
Current reading's percentile 100

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on REPL